Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Medicine
FDA Approves Nivolumab With AVD for Advanced Hodgkin Lymphoma
The FDA approved nivolumab with doxorubicin, vinblastine and dacarbazine for adults and pediatric patients 12 and older with previously untreated stage III or IV classical Hodgkin lymphoma.
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
The FDA approved nivolumab with AVD chemotherapy on 20 March for adults and pediatric patients 12 years and older with previously untreated stage III or IV classical Hodgkin lymphoma.
FDA also granted traditional approval to nivolumab for specified adult relapsed or refractory classical Hodgkin lymphoma indications.
Classical Hodgkin lymphoma is often highly treatable, but front-line regimens still need to balance cure rates with long-term toxicity, especially for younger patients.
Sourcing note: Indication language and approval status are from FDA. The article does not compare the regimen against other standard front-line approaches.
Why It Matters
Bringing immunotherapy into earlier Hodgkin lymphoma treatment can shift the balance between efficacy and toxicity. Pediatric inclusion also makes long-term safety and survivorship considerations especially important.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDANivolumabHodgkin LymphomaOncologyPediatrics